Ascendis Pharma A/s Stock Earnings Reports

Ascendis Pharma reported strong Q1 2026 progress: commercial momentum after FDA approval of YUVIWEL (their third FDA-approved TransCon product), continued revenue growth and profitability, and an expanding pipeline. Q1 revenue was EUR 247 million (including EUR 197 million from YORVIPATH and EUR 44 million from SKYTROFA) with two one-time impacts to YORVIPATH (~EUR 15 million combined). The company is profitable on both IFRS and non-IFRS bases (operating profit EUR 25 million; non-IFRS operating profit EUR 55 million). Cash and liquidity actions included completing a direct NASDAQ listing, redeeming convertible notes, repurchasing shares (~EUR 60 million impact), and signing a USD 187.5 million sale of a Priority Review Voucher (PRV). Commercial highlights: >6,300 patients prescribed YORVIPATH globally (>1,000 new U.S. prescriptions in Q1), improving U.S. reimbursement metrics (upstream coverage ~80%, mid-70% cumulative approval), SKYTROFA maintaining ~7% GH market share in the U.S., and early uptake of YUVIWEL (60+ children prescribed within weeks of launch). Key pipeline notes: promising Phase II combo results (TransCon CNP + TransCon GH) in hypochondroplasia with potential to reduce need for major surgeries; ongoing partnerships (e.g., with Novo Nordisk) and planned clinic entries for other TransCon programs. Management reiterated focus on scaling revenues and operating margins through 2026, continued R&D investment, and further geographic and label expansions for their products.